FindTrial
Sign In

Diagnosis of severe pneumonia using new laboratory and radiological parameters.

Development of screening tool to identify fatal hyperinflammatory subphenotype-2 of acute respiratory distress syndrome (ARDS) with Point-of-Care Ultrasound, ventilatory mechanical power, and blood cell count-derived biomarkers. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/01/061829
Enrollment
289
Registered
2024-01-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J80- Acute respiratory distress syndrome

Interventions

Control Intervention1: NIL: NIL

Sponsors

SHWETHAPRIYA R
Lead Sponsor
SOUVIK CHAUDHURI
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Adult ARDS patients as per Berlin criteria

Exclusion criteria

Exclusion criteria: Patients with ARDS diagnosis > 24 hours. Patients of ARDS, not on IMV. Lung trauma, chest wall deformities where POCUS may be unreliable. Previously known causes of right ventricular dysfunction. Patients on previous corticosteroids where NLR, SIII ratio will be unreliable. Patients with known CKD where Renal arterial Resistive Index (RII) will be unreliable.

Design outcomes

Primary

MeasureTime frame
Primary: Mortality at 28 days from ARDS diagnosis Timepoint: 28 days—

Secondary

MeasureTime frame
Length of ICU and hospital stayTimepoint: 60 days—

Countries

India

Contacts

Public ContactShwethapriya R

Kasturba Medical College, MANIPAL, Manipal Academy of Higher Education, Manipal

shwethapriya.rao@manipal.edu09964668404

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026